2024

• Berglund, L. (2024). Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective. Journal of Clinical Immunology, 44(1), 34. [More Information]

2022

• Lee, A., Hannaford, A., Vucic, S., Berglund, L. (2022). Chronic inflammatory demyelinating polyneuropathy after commencement of dupilumab for atopic dermatitis: Coincidence or contributory? Annals of Allergy, Asthma, & Immunology, 128(1), 105-106. [More Information]

2021

• Emerson, J., van der Poorten, D., Lin, M., Chou, S., McLeod, D., Berglund, L. (2021). Duodenal plasma cells correspond to serum IgA in common variable immunodeficiency. Pathology, 53(4), 503-507. [More Information]
• Cai, F., Dai, P., Jiang, J., Lee, A., Emerson, J., Taylor, M., Kang, M., Kwong, K., Clark, H., Wong, S., Berglund, L., Schifter, M., Lin, M., et al (2021). Treatment and monitoring of an immunobullous disease cohort in a single centre in Sydney Australia. Australasian Journal of Dermatology, 62(3), e437-e440. [More Information]
• Emerson, J., Lee, E., Berglund, L. (2021). Treatment of Immune Dysregulation Due to a PTEN Variant with Sirolimus. Journal of Clinical Immunology, 41(5), 1085-1088. [More Information]
• Marais, B., Chong, E., Fernando, S., Daniel, S., Watts, M., Berglund, L., Barry, S., Kotsiou, G., Headley, A., Stapledon, R. (2021). Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions. Open Forum Infectious Diseases, 8(1), ofaa604. [More Information]

2020

• Lau, A., Lau, A., Avery, D., Jackson, K., Lenthall, H., Volpi, S., Brigden, H., Russell, A., Bier, J., Bier, J., Berglund, L., et al (2020). Activated PI3K delta breaches multiple B cell tolerance checkpoints and causes autoantibody production. The Journal of Experimental Medicine, 217(2), 1-21. [More Information]
• Yap, J., Gloss, B., Batten, M., Hsu, P., Berglund, L., Cai, F., Dai, P., Parker, A., Qiu, M., Miley, W., Wu, K., et al (2020). Everolimus-Induced Remission of Classic Kaposi’s Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency. Journal of Clinical Immunology, 40, 774?779. [More Information]

2019

• Bier, J., Rao, G., Payne, K., Brigden, H., French, E., Pelham, S., Lau, A., Lenthall, H., Edwards, E., Smart, J., Berglund, L., Hsu, P., Wong, M., et al (2019). Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells. Journal of Allergy and Clinical Immunology, 144(1), 236-253. [More Information]
• Edwards, E., Bier, J., Cole, T., Wong, M., Hsu, P., Berglund, L., Boztug, K., Lau, A., Gostick, E., Price, D., et al (2019). Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation, function and EBV immunity. Journal of Allergy and Clinical Immunology, 143(1), 276-291.e6. [More Information]

2018

• Avery, D., Kane, A., Nguyen, T., Lau, A., Nguyen, A., Lenthall, H., Payne, K., Shi, W., Brigden, H., French, E., Elliott, M., Berglund, L., et al (2018). Germline-activating mutations in PIK3CD compromise B cell development and function. The Journal of Experimental Medicine, 215(8), 2073-2095. [More Information]
• Jiang, J., Kakar, F., Wing, H., Bhattacharyya, A., Berglund, L. (2018). The case of the interfering IgM. Pathology, 50(4), 455-484. [More Information]

2017

• Chandratilleke, D., Anantharajah, A., Vicaretti, M., Benson, W., Berglund, L. (2017). Migratory large vessel vasculitis preceding acute myeloid leukemia: a case report. Journal of Medical Case Reports, 11(1), 1-4. [More Information]
• Hu, H., Nayyar, R., Berglund, L., Anderson, E. (2017). Pregnancy in a patient with congenital analbuminaemia. BMJ Case Reports, 2017, bcr2016218093. [More Information]

2015

• Berglund, L., van der Poorten, D., Caridi, G., Campagnoli, M., Minchiotti, L. (2015). Congenital analbuminaemia diagnosed in adulthood in an Australian family. Pathology, 47(5), 492-494. [More Information]

2013

• Berglund, L., Avery, D., Ma, C., Moens, L., Deenick, E., Bustamante, J., Boisson-Dupuis, S., Wong, M., Adelstein, S., Arkwright, P., et al (2013). IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood, 122(24), 3940-3950. [More Information]
• Deenick, E., Avery, D., Chan, A., Berglund, L., Ives, M., Moens, L., Stoddard, J., Bustamante, J., Boisson-Dupuis, S., Tsumura, M., Adelstein, S., et al (2013). Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. The Journal of Experimental Medicine, 210(12), 2739-2753. [More Information]

2011

• Recher, M., Berglund, L., Avery, D., Cowan, M., Gennery, A., Smart, J., Peake, J., Wong, M., Pai, S., Palendira, U., et al (2011). IL-21 is the primary common (upsilon) chain-binding cytokine required for human B-cell differentiation in vivo. Blood, 118(26), 6824-6835. [More Information]

2008

• Berglund, L., Wong, S., Fulcher, D. (2008). B-cell maturation defects in common variable immunodeficiency and association with clinical features. Pathology, 40(3), 288-294. [More Information]

2006

• Berglund, L., Jones, G., Murali, R., Fulcher, D. (2006). TACI mutation with invasive polyclonal CD8+ T-cell lymphoproliferation in a patient with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 117(4), 870-877. [More Information]